Homocitrulline is Associated with Cardiovascular Outcomes in Non-Dialysis Patients with CKD.

Date publication

avril 2025

Journal

Kidney360

Auteurs

Membres identifiés du Cancéropôle Est :
Pr GILLERY Philippe

Tous les auteurs :
Laville SM, Jaisson S, Gillery P, Okwieka A, Alencar de Pinho N, Combe C, Mansencal N, Massy ZA, Liabeuf S,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40168087

Résumé

Protein carbamylation contributes to an increase in the cardiovascular risk in certain patient populations (e.g. in patients with chronic kidney disease (CKD) because of elevated urea concentrations). Homocitrulline (HCit) is a biomarker of overall protein carbamylation. In a study of a large cohort of non-dialysis patients with a confirmed diagnosis of CKD and an estimated glomerular filtration rate (eGFR) <60mL/min/1.73m2, we sought to determine whether the serum HCit concentration was associated with adverse cardiovascular outcomes and all-cause mortality.

Référence

Kidney360. 2025 04 1;: